Caseware UK (AP4) 2023.0.135 2023.0.135 2024-12-31 false 2024-01-01 false false 06492838 2024-01-01 2024-12-31 06492838 2023-01-01 2023-12-31 06492838 2024-12-31 06492838 2023-12-31 06492838 2023-01-01 06492838 c:PriorPeriodIncreaseDecrease 2024-01-01 2024-12-31 06492838 5 2024-01-01 2024-12-31 06492838 5 2023-01-01 2023-12-31 06492838 1 2024-01-01 2024-12-31 06492838 e:Director1 2024-01-01 2024-12-31 06492838 e:Director2 2024-01-01 2024-12-31 06492838 e:Director2 2024-12-31 06492838 e:Director3 2024-01-01 2024-12-31 06492838 e:Director3 2024-12-31 06492838 e:Director4 2024-01-01 2024-12-31 06492838 e:Director4 2024-12-31 06492838 e:Director5 2024-01-01 2024-12-31 06492838 e:RegisteredOffice 2024-01-01 2024-12-31 06492838 c:PlantMachinery 2024-01-01 2024-12-31 06492838 c:PlantMachinery 2024-12-31 06492838 c:PlantMachinery 2023-12-31 06492838 c:PlantMachinery c:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 06492838 c:OfficeEquipment 2024-01-01 2024-12-31 06492838 c:ComputerEquipment 2024-12-31 06492838 c:ComputerEquipment 2023-12-31 06492838 c:ComputerEquipment c:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 06492838 c:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 06492838 c:PatentsTrademarksLicencesConcessionsSimilar 2024-01-01 2024-12-31 06492838 c:ComputerSoftware 2024-12-31 06492838 c:ComputerSoftware 2023-12-31 06492838 c:CurrentFinancialInstruments 2024-12-31 06492838 c:CurrentFinancialInstruments 2023-12-31 06492838 c:Non-currentFinancialInstruments 2024-12-31 06492838 c:Non-currentFinancialInstruments 2023-12-31 06492838 c:CurrentFinancialInstruments c:WithinOneYear 2024-12-31 06492838 c:CurrentFinancialInstruments c:WithinOneYear 2023-12-31 06492838 c:Non-currentFinancialInstruments c:AfterOneYear 2024-12-31 06492838 c:Non-currentFinancialInstruments c:AfterOneYear 2023-12-31 06492838 c:Non-currentFinancialInstruments c:BetweenOneTwoYears 2024-12-31 06492838 c:Non-currentFinancialInstruments c:BetweenOneTwoYears 2023-12-31 06492838 c:Non-currentFinancialInstruments c:BetweenTwoFiveYears 2024-12-31 06492838 c:Non-currentFinancialInstruments c:BetweenTwoFiveYears 2023-12-31 06492838 c:ShareCapital 2024-01-01 2024-12-31 06492838 c:ShareCapital 2024-12-31 06492838 c:ShareCapital 2023-01-01 2023-12-31 06492838 c:ShareCapital 2023-12-31 06492838 c:ShareCapital 2023-01-01 06492838 c:SharePremium 2024-01-01 2024-12-31 06492838 c:SharePremium 2024-12-31 06492838 c:SharePremium c:PriorPeriodIncreaseDecrease 2024-01-01 2024-12-31 06492838 c:SharePremium 2023-01-01 2023-12-31 06492838 c:SharePremium 2023-12-31 06492838 c:SharePremium 2023-01-01 06492838 c:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 06492838 c:RetainedEarningsAccumulatedLosses 2024-12-31 06492838 c:RetainedEarningsAccumulatedLosses c:PriorPeriodIncreaseDecrease 2024-01-01 2024-12-31 06492838 c:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 06492838 c:RetainedEarningsAccumulatedLosses 2023-12-31 06492838 c:RetainedEarningsAccumulatedLosses 2023-01-01 06492838 c:AcceleratedTaxDepreciationDeferredTax 2024-12-31 06492838 c:AcceleratedTaxDepreciationDeferredTax 2023-12-31 06492838 c:TaxLossesCarry-forwardsDeferredTax 2024-12-31 06492838 c:TaxLossesCarry-forwardsDeferredTax 2023-12-31 06492838 e:OrdinaryShareClass1 2024-01-01 2024-12-31 06492838 e:OrdinaryShareClass1 2023-01-01 2023-12-31 06492838 e:OrdinaryShareClass1 2024-12-31 06492838 e:OrdinaryShareClass1 2023-12-31 06492838 e:OrdinaryShareClass2 2024-01-01 2024-12-31 06492838 e:OrdinaryShareClass2 2023-01-01 2023-12-31 06492838 e:OrdinaryShareClass2 2024-12-31 06492838 e:OrdinaryShareClass2 2023-12-31 06492838 e:FRS102 2024-01-01 2024-12-31 06492838 e:Audited 2024-01-01 2024-12-31 06492838 e:FullAccounts 2024-01-01 2024-12-31 06492838 e:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 06492838 c:WithinOneYear 2024-12-31 06492838 c:WithinOneYear 2023-12-31 06492838 c:BetweenOneFiveYears 2024-12-31 06492838 c:BetweenOneFiveYears 2023-12-31 06492838 c:HirePurchaseContracts c:WithinOneYear 2024-12-31 06492838 c:HirePurchaseContracts c:WithinOneYear 2023-12-31 06492838 c:HirePurchaseContracts c:BetweenOneFiveYears 2024-12-31 06492838 c:HirePurchaseContracts c:BetweenOneFiveYears 2023-12-31 06492838 c:HirePurchaseContracts c:MoreThanFiveYears 2024-12-31 06492838 c:HirePurchaseContracts c:MoreThanFiveYears 2023-12-31 06492838 c:PlantMachinery c:LeasedAssetsHeldAsLessee 2024-12-31 06492838 c:PlantMachinery c:LeasedAssetsHeldAsLessee 2023-12-31 06492838 f:PoundSterling 2024-01-01 2024-12-31 06492838 c:ShareCapital c:PriorPeriodErrorIncreaseDecrease 2024-01-01 2024-12-31 06492838 c:RetainedEarningsAccumulatedLosses c:PreviouslyStatedAmount 2023-12-31 06492838 c:PreviouslyStatedAmount 2023-12-31 iso4217:GBP xbrli:shares xbrli:pure

The Thornbury Radiosurgery Centre Limited Registered number: 06492838 Annual Report For the year ended 31 December 2024
THE THORNBURY RADIOSURGERY CENTRE LIMITED COMPANY INFORMATION
Directors | G Shetty
| S H Carré
| A E B Nelson
| S B Burns
Registered number | 06492838
Registered office | 42-43 Queen Square
| London
| England
| WC1N 3AJ
Independent auditor | Forvis Mazars LLP
| Chartered Accountants & Statutory Auditor
| 30 Old Bailey
| London
| EC4M 7AU
THE THORNBURY RADIOSURGERY CENTRE LIMITED CONTENTS
| Page
Directors' Report | 1 - 3
Independent Auditor's Report | 4 - 7
Statement of Comprehensive Income | 8
Statement of Financial Position | 9 - 10
Statement of Changes in Equity | 11
Notes to the Financial Statements | 12 - 24
THE THORNBURY RADIOSURGERY CENTRE LIMITED DIRECTORS' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 The directors present their Annual Report and the audited financial statements of The Thornbury Radiosurgery Centre Limited (the 'Company') for the year ended 31 December 2024.
Principal activity
The principal activity of the Company is to provide specialised intracranial stereotactic radiosurgery treatments for NHS and private patients. The Company currently operates a "support" service for the National Centre for Stereotactic Radiosurgery at the Royal Hallamshire Hospital, Sheffield. It offers an Elekta ICON GammaKnife service to provide specialised treatment primarily for the effective treatment of Brain Metastases and Skull Based Brain Tumours only.
Results and dividends
During the year the Company generated a total revenue of £1,880,937 (2023: £1,621,609). The loss for the year after taxation amounted to £155,798 (Restated 2023: loss of £320,946). The directors do not recommend the payment of a dividend for the year (2023: £nil).
Directors
The directors who served during the year and up to the date of this report were:
G Shetty (appointed 4 March 2024)
S H Carré (appointed 29 November 2024)
A E B Nelson (appointed 29 November 2024)
S A Doroszkowski (resigned 31 October 2024) S B Burns (appointed 19 March 2025)
Directors' responsibilities statement
The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations. Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to: ∙select suitable accounting policies for the Company's financial statements and then apply them consistently; ∙make judgements and accounting estimates that are reasonable and prudent; and ∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business. The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. - 1 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024
Going concern
The financial statements are prepared on a going concern basis. At the year end, the Company had net current liabilities of £272,629 (2023: net current liabilities of £229,497). The Company remains assured of the financial support by the parent company. The directors have received confirmation that the parent company will make available sufficient funds to the Company to enable the Company to continue as a going concern for at least twelve months from the date of signature of the audit report. On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis.
Research and development activities
The Company did not undertake any new research and development activities during the year. Existing services were maintained and supported as part of normal operational activities.
Qualifying third party indemnity provisions
The Company has made qualifying third party indemnity provisions for the benefit of its Directors which were made during the year and remain in force at the date of this report. No claim or notice of claim in respect of these indemnities has been received in the year.
Provision of information to the auditor
Each of the persons who are directors at the time when this Directors' Report is approved has confirmed that: ∙so far as the directors are aware, there is no relevant audit information of which the Company's auditor is unaware; and ∙the directors have taken all the steps that ought to have been taken as directors in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.
Post balance sheet events
On 22 April 2025, the Amethyst Group extended an existing loan facility with Ares Management Limited and borrowed 30 million Euros under committed facilities in order to finance the acquisition of the Centre de Radiotherapie et D'Oncologie de Moyenne Garibbe by Amethyst France in a transaction that was completed on 28 February 2025. The charge includes fixed charges, floating charges, negative pledge clauses and is held over the assets of the Company. Furthermore, in an agreement that was signed on 25 April 2025, the shareholders of the Company's parent, Amethyst Top BV, agreed to sell 100% of the equity in the Group to funds controlled by Fremmen Capital. The sale was completed on 7 August 2025.
Auditor
The auditor, Forvis Mazars LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. - 2 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024
Small companies note
In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006. This report was approved by the board and signed on its behalf by:
G Shetty Director
Date: 20 August 2025
- 3 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE THORNBURY RADIOSURGERY CENTRE LIMITED Opinion We have audited the financial statements of The Thornbury Radiosurgery Centre Limited (the ‘Company’) for the year ended 31 December 2024 which comprise the Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Changes in Equity and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice). In our opinion, the financial statements: ∙give a true and fair view of the state of the Company’s affairs as at 31 December 2024 and of its loss for the year then ended; ∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and ∙have been prepared in accordance with the requirements of the Companies Act 2006. Basis for opinion We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. Other information The other information comprises the information included in the Annual Report, other than the financial statements and our auditor’s report thereon. The directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. - 4 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE THORNBURY RADIOSURGERY CENTRE LIMITED Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Opinions on other matters prescribed by the Companies Act 2006 In our opinion, based on the work undertaken in the course of the audit: ∙the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and ∙the Directors' Report has been prepared in accordance with applicable legal requirements. Matters on which we are required to report by exception In light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion: ∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or ∙the financial statements are not in agreement with the accounting records and returns; or ∙certain disclosures of directors' remuneration specified by law are not made; or ∙we have not received all the information and explanations we require for our audit; or ∙the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemption in preparing the Directors' Report and from the requirement to prepare a Strategic Report. - 5 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE THORNBURY RADIOSURGERY CENTRE LIMITED Responsibilities of Directors As explained more fully in the Directors' Responsibilities Statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors intend either to liquidate the Company or to cease operations, or have no realistic alternative but to do so. Auditor's responsibilities for the audit of the financial statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. Based on our understanding of the Company and its industry, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation, anti-money laundering regulation, non-compliance with implementation of government support schemes relating to COVID-19. To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to: ∙Inquiring of management and, where appropriate, those charged with governance, as to whether the Company is in compliance with laws and regulations, and discussing their policies and procedures regarding compliance with laws and regulations; ∙Inspecting correspondence, if any, with relevant licensing or regulatory authorities; ∙Communicating identified laws and regulations to the engagement team and remaining alert to any indications of non-compliance throughout our audit; and ∙Considering the risk of acts by the Company which were contrary to applicable laws and regulations, including fraud. - 6 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF THE THORNBURY RADIOSURGERY CENTRE LIMITED We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as tax legislation, pension legislation, the Companies Act 2006. In addition, we evaluated the directors' and management’s incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of override of controls, and determined that the principal risks were related to posting manual journal entries to manipulate financial performance, in particular to revenue recognition (which we pinpointed to the occurrence assertion) and significant one-off or unusual transactions. Our audit procedures in relation to fraud included but were not limited to: ∙Making enquiries of the directors and management on whether they had knowledge of any actual, suspected or alleged fraud; ∙Gaining an understanding of the internal controls established to mitigate risks related to fraud; ∙Discussing amongst the engagement team the risks of fraud; and ∙Addressing the risks of fraud through management override of controls by performing journal entry testing. There are inherent limitations in the audit procedures described above and the primary responsibility for the prevention and detection of irregularities including fraud rests with management. As with any audit, there remained a risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal controls. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. Use of the audit report This report is made solely to the Company's members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body for our audit work, for this report, or for the opinions we have formed. Sameena Fonseca (Senior statutory auditor) for and on behalf of Forvis Mazars LLP Chartered Accountants and Statutory Auditor 30 Old Bailey London Surrey EC4M 7AU 20 August 2025 - 7 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2024
| 2024 | Restated 2023
| £ | £
Turnover | 1,880,937 | 1,621,609
Cost of sales | (847,734) | (806,555)
Gross profit | 1,033,203 | 815,054
Administrative expenses | (920,160) | (910,521)
Other operating charges | (286,440) | (208,019)
Operating loss | (173,397) | (303,486)
Interest payable and similar expenses | (12,490) | (24,075)
Loss before tax | (185,887) | (327,561)
Tax on loss | 30,089 | 6,615
Loss for the financial year | (155,798) | (320,946)
Other comprehensive income | - | -
Total comprehensive loss for the year | (155,798) | (320,946)
The Statement of Comprehensive Income has been prepared on the basis that all operations are continuing operations. The notes on pages 12 to 24 form part of these financial statements.
- 8 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED REGISTERED NUMBER: 06492838 STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2024
|  | 2024 |  | Restated 2023
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Intangible assets | 6 |  | - |  | -
Tangible assets | 7 |  | 215,437 |  | 474,871
|  |  | 215,437 |  | 474,871
Current assets |  |  |  |  |
Debtors: Amounts falling due within one year | 8 | 569,706 |  | 1,112,160 |
Cash and cash equivalents |  | 1,753 |  | 18,020 |
|  | 571,459 |  | 1,130,180 |
Creditors: Amounts falling due within one year | 9 | (844,088) |  | (1,359,677) |
Net current liabilities |  |  | (272,629) |  | (229,497)
Total assets less current liabilities |  |  | (57,192) |  | 245,374
Creditors: Amounts falling due after more than one year | 10 |  | - |  | (124,666)
Provisions for liabilities |  |  |  |  |
Deferred tax | 13 | - |  | (22,102) |
|  |  | - |  | (22,102)
Net (liabilities)/assets |  |  | (57,192) |  | 98,606
Capital and reserves |  |  |  |  |
Called up share capital | 14 |  | 900 |  | 900
Share premium account |  |  | 589,100 |  | 589,100
Profit and loss account |  |  | (647,192) |  | (491,394)
Total equity |  |  | (57,192) |  | 98,606
- 9 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED REGISTERED NUMBER: 06492838 STATEMENT OF FINANCIAL POSITION (CONTINUED) AS AT 31 DECEMBER 2024 The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
G Shetty
Director
Date: 20 August 2025
The notes on pages 12 to 24 form part of these financial statements. - 10 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2024
| Called up share capital | Share premium account | Profit and loss account | Total equity
| £ | £ | £ | £
At 1 January 2023 | 900 | 589,100 | (170,448) | 419,552
Comprehensive loss for the year |  |  |  |
Loss for the year | - | - | (320,946) | (320,946)
Total comprehensive loss for the year | - | - | (320,946) | (320,946)
At 1 January 2024 (as previously stated) | 900 | 589,100 | (421,383) | 168,617
Prior year adjustment | - | - | (70,011) | (70,011)
At 1 January 2024 (as restated) | 900 | 589,100 | (491,394) | 98,606
Comprehensive loss for the year |  |  |  |
Loss for the year | - | - | (155,798) | (155,798)
Total comprehensive loss for the year | - | - | (155,798) | (155,798)
At 31 December 2024 | 900 | 589,100 | (647,192) | (57,192)
| The notes on pages 12 to 24 form part of these financial statements.
- 11 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
1. | General information
The Thornbury Radiosurgery Centre Limited (the 'Company') a private company limited by shares incorporated in England and Wales. The registered number of the Company is 06492838. Its registered office is 42-43 Queen Square, London, England, WC1N 3AJ. The principal activity of the Company is to provide specialised intracranial stereotactic radiosurgery treatments for NHS and private patients. The Company currently operates a "support" service for the National Centre for Stereotactic Radiosurgery at the Royal Hallamshire Hospital, Sheffield. It offers an Elekta ICON GammaKnife service to provide specialised treatment primarily for the effective treatment of Brain Metastases and Skull Based Brain Tumours only. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The financial statements have been presented in Pound Sterling as this is the currency of the primary economic environment in which the Company operates and is rounded to the nearest pound. The following principal accounting policies have been applied:
| 2.2 | Going concern
The financial statements are prepared on a going concern basis. At the year end, the Company had net current liabilities of £272,629 (2023: net current liabilities of £229,497). The Company remains assured of the financial support by the parent company. The directors have received confirmation that the parent company will make available sufficient funds to the Company to enable the Company to continue as a going concern for at least twelve months from the date of signature of the audit report. On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis.
| 2.3 | Turnover
Turnover from the rendering of services is recognised at the date on which the treatment provided by the Company is performed. Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Company and turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable at the point of treatment, excluding discounts, rebates, value added tax and other sales taxes. The Company’s income is derived from a mix of NHS and private services. For the year under review: The Company reported 72% NHS-derived revenue and 28% from private patients, with patient volumes at 92% NHS and 8% private. These figures reflect a higher revenue contribution per private patient, which is consistent with the differing pricing structures between NHS and private work. The directors continue to monitor the balance between NHS and private activity to ensure long-term sustainability and quality of service across both patient groups. - 12 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.4 | Operating leases: the Company as lessee
Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term. Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.
| 2.5 | Leased assets: the Company as lessee
Assets obtained under hire purchase contracts and finance leases are capitalised as tangible fixed assets. Assets acquired by finance lease are depreciated over the shorter of the lease term and their useful lives. Assets acquired by hire purchase are depreciated over their useful lives. Finance leases are those where substantially all of the benefits and risks of ownership are assumed by the Company. Obligations under such agreements are included in creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to profit or loss so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.
| 2.6 | Interest payable and similar expenses
Interest payable and similar expenses are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.7 | Government loans
The Group has taken advantage of the governments' Coronavirus Bounce Back Loan Scheme (BBLS). This has been accounted for as a basic financial instrument under the amortised cost method using an effective interest rate. Any finance charge incurred is presented in the Statement of Comprehensive Income within 'interest payable and similar expenses'.
| 2.8 | Pensions
Defined contribution pension plan The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations. The contributions are recognised as an expense in the Statement of Comprehensive Income when they fall due. Amounts not paid are shown in other creditors as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds. - 13 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.9 | Current and deferred taxation
The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of Comprehensive Income except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.
| 2.10 | Intangible assets
Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years. The estimated useful lives range as follows:
|  |  |  | Computer software | - | 3 | years
Amortisation is charged to 'administrative expenses' in the Statement of Comprehensive Income. - 14 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.11 | Tangible assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. At each reporting date the Company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provided on the following basis:
|  |  |  | Plant and machinery | - | 3-5 years
|  |  |  | Equipment | - | 10 years
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of Comprehensive Income. Depreciation is charged to 'administrative expenses' in the Statement of Comprehensive Income.
| 2.12 | Debtors: Amounts falling due within one year
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.13 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.
| 2.14 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. - 15 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.15 | Financial instruments
Financial instruments are recognised in the Company's Statement of Financial Position when the Company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments. Impairment of financial assets Financial assets are assessed for indicators of impairment at each reporting date. Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial assets have been negatively impacted, leading to a reduction in the asset's value. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the assets original effective interest rate. If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the Statement of Comprehensive Income. Financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities. Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial. Debt instruments are subsequently carried at their amortised cost using the effective interest rate method. - 16 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2.Accounting policies (continued)
| 2.15 | Financial instruments (continued)
Financial liabilities (continued) Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. Derecognition of financial instruments Derecognition of financial assets Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained. Derecognition of financial liabilities Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.
| 2.16 | Prior year restatement
Following the identification of an error in the prior year financial statements, it was discovered administrative expenses and the amounts owed to group undertakings were understated. The results for the year ended 31 December 2023 are therefore restated to reflect a correction of the material error representing a movement totalling £70,011 to increase the administrative expenses and an increase in amounts owed to group undertakings of £70,011. This resulted in an increase in the loss for the year by £70,011 and decrease in net assets of the same. - 17 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
3. | Judgements in applying accounting policies and key sources of estimation uncertainty
In applying the Company’s accounting policies, the Directors are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The Directors’ judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable. Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods. 3.1 Critical judgements in applying the Company’s accounting policies The Directors do not consider there to be any critical judgements made in the process of applying the Company’s accounting policies. 3.2 Key sources of estimation uncertainty The Directors do not consider there to be any key sources of estimation uncertainty.
4. | Other operating charges
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Other operating charges | 286,440 | 208,019
| Other operating charges relate to intercompany recharges to the Company.
5. | Employees
| The average monthly number of employees, including the directors, during the year was 6 (2023: 5).
- 18 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
6. | Intangible assets
|  | Computer software
|  | £
| Cost |
| At 1 January 2024 | 40,232
| At 31 December 2024 | 40,232
| Accumulated amortisation |
| At 1 January 2024 | 40,232
| At 31 December 2024 | 40,232
| Net book value |
| At 31 December 2024 | -
| At 31 December 2023 | -
- 19 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
7. | Tangible assets
|  | Plant and machinery | Equipment | Total
|  | £ | £ | £
| Cost |  |  |
| At 1 January 2024 | 4,177,377 | 1,982,603 | 6,159,980
| At 31 December 2024 | 4,177,377 | 1,982,603 | 6,159,980
| Accumulated depreciation |  |  |
| At 1 January 2024 | 3,738,372 | 1,946,737 | 5,685,109
| Charge for the year | 241,433 | 18,001 | 259,434
| At 31 December 2024 | 3,979,805 | 1,964,738 | 5,944,543
| Net book value |  |  |
| At 31 December 2024 | 197,572 | 17,865 | 215,437
| At 31 December 2023 | 439,005 | 35,866 | 474,871
| The net book value of assets held under finance leases or hire purchase contracts, included above, are as follows:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Plant and machinery | 197,572 | 439,005
- 20 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
8. | Debtors: Amounts falling due within one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Trade debtors | 92,599 | 100,320
| Amounts owed by group undertakings | 418,777 | 990,551
| Prepayments | 50,343 | 21,289
| Deferred taxation | 7,987 | -
|  | 569,706 | 1,112,160
| Amounts owed by group undertakings are unsecured, interest free and payable on demand.
9. | Creditors: Amounts falling due within one year
|  |  |  |  | 2024 | Restated 2023
|  |  |  |  | £ | £
| Bank loans (note 10) | - | 10,000
| Trade creditors | 84,430 | 370,045
| Amounts owed to group undertakings | 483,548 | 609,978
| Obligations under finance lease and hire purchase contracts | 102,161 | 195,660
| Other creditors | 42,846 | 77,123
| Accruals and deferred income | 131,103 | 96,871
|  | 844,088 | 1,359,677
| Amounts owed to group undertakings are unsecured, interest free and repayable on demand.
10. | Creditors: Amounts falling due after more than one year
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Bank loans (note 10) | - | 22,500
| Net obligations under finance leases and hire purchase contracts | - | 102,166
|  | - | 124,666
- 21 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
11. | Loans
| Analysis of the maturity of loans is given below:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Amounts falling due within one year |  |
| Bank loans | - | 10,000
|  | - | 10,000
| Amounts falling due 1-2 years |  |
| Bank loans | - | 10,000
|  | - | 10,000
| Amounts falling due 2-5 years |  |
| Bank loans | - | 12,500
|  | - | 12,500
|  | - | 32,500
| The bank loan relates to Coronavirus Bounce Back Loan Scheme (BBLS) and was repaid in full during the year. The loan attracted an interest rate of 2.5%.
12. | Finance leases
| Minimum lease payments under finance leases fall due as follows:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Within one year | 103,896 | 207,792
| Between 1-5 years | - | 103,896
| Less: Future finance charges | (1,735) | (13,862)
|  | 102,161 | 297,826
| Finance leases attract an interest rate of 3.09% and are repayable over 5 years at an amount of £17,316 per month.
- 22 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
13. | Deferred taxation
|  | 2024
|  | £
| At beginning of year | (22,102)
| Charged to profit or loss | 30,089
| At end of year | 7,987
| The deferred taxation balance is made up as follows:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Fixed asset timing differences | 7,588 | (20,348)
| Short timing differences | 399 | (1,754)
|  | 7,987 | (22,102)
14. | Called up share capital
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 450 (2023: 450) Ordinary A shares of £1 each | 450 | 450
|  | 450 (2023: 450) Ordinary B shares of £1 each | 450 | 450
|  |  | 900 | 900
| All shares rank pari passu in respect of voting rights, entitlement to distributions and participation.
15. | Pension commitments
The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. There were no amounts payable to the fund at the year end (2023: £nil).
16. | Capital commitments
On 29 April 2024 a charge was registered by Ares Management Limited over the Company. The charge included fixed charges, floating charges, negative pledge clauses and was held over the assets of the Company. - 23 -
THE THORNBURY RADIOSURGERY CENTRE LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
17. | Commitments under operating leases
| At 31 December 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:
|  |  |  |  | 2024 | 2023
|  |  |  |  | £ | £
| Not later than 1 year | 115,154 | 115,154
| Later than 1 year and not later than 5 years | 331,668 | 446,822
|  | 446,822 | 561,976
18. | Related party transactions
| The Company has taken advantage of the exemption under paragraph 33.1A of Financial Reporting Standard 102 not to disclose transactions with other wholly owned members of the Group.
19. | Post balance sheet events
On 22 April 2025, the Amethyst Group extended an existing loan facility with Ares Management Limited and borrowed 30 million Euros under committed facilities in order to finance the acquisition of the Centre de Radiotherapie et D'Oncologie de Moyenne Garibbe by Amethyst France in a transaction that was completed on 28 February 2025. The charge includes fixed charges, floating charges, negative pledge clauses and is held over the assets of the Company. Furthermore, in an agreement that was signed on 25 April 2025, the shareholders of the Company's parent, Amethyst Top BV, agreed to sell 100% of the equity in the Group to funds controlled by Fremmen Capital. The sale was completed on 7 August 2025.
20. | Controlling party
Medical Equipment Solutions Limited a company registered in England and Wales, is the immediate parent company. The registered address of the immediate parent undertaking is 42-43 Queen Square, London, England, WC1N 3AJ. Amethyst Top B.V. (a company registered in the Netherlands) is the ultimate parent company. The registered address of the ultimate parent undertaking is Spicalaan 39, 2132 JG Hoofddorp, the Netherlands. The smallest and largest group into which the entity is consolidated is Amethyst Top B.V., a company registered in the Netherlands. Copies of the accounts for Amethyst Top B.V. are available to the public and may be obtained from Spicalaan 39, 2132 JG Hoofddorp, the Netherlands.
- 24 -